18,240 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by Cinctive Capital Management LP

Cinctive Capital Management LP bought a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,240 shares of the biopharmaceutical company’s stock, valued at approximately $4,292,000.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Quantbot Technologies LP lifted its position in Alnylam Pharmaceuticals by 1,754.5% in the 3rd quarter. Quantbot Technologies LP now owns 204 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 193 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Alnylam Pharmaceuticals by 34.4% in the third quarter. Captrust Financial Advisors now owns 4,833 shares of the biopharmaceutical company’s stock valued at $1,329,000 after purchasing an additional 1,237 shares during the period. Investment Management Corp of Ontario raised its holdings in shares of Alnylam Pharmaceuticals by 153.5% during the third quarter. Investment Management Corp of Ontario now owns 7,059 shares of the biopharmaceutical company’s stock valued at $1,941,000 after buying an additional 4,274 shares during the last quarter. Parkman Healthcare Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $7,009,000. Finally, Quantinno Capital Management LP grew its holdings in Alnylam Pharmaceuticals by 50.3% in the 3rd quarter. Quantinno Capital Management LP now owns 3,366 shares of the biopharmaceutical company’s stock worth $926,000 after buying an additional 1,126 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on ALNY shares. Citigroup boosted their price target on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. Stifel Nicolaus upped their price objective on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday. Canaccord Genuity Group raised their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday, March 21st. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 21st. Finally, Redburn Atlantic began coverage on shares of Alnylam Pharmaceuticals in a research note on Monday. They set a “buy” rating and a $353.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $316.25.

Alnylam Pharmaceuticals Stock Up 4.3 %

Shares of NASDAQ:ALNY opened at $266.83 on Thursday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The company has a market cap of $34.71 billion, a PE ratio of -122.96 and a beta of 0.30. The firm has a 50 day simple moving average of $260.16 and a 200 day simple moving average of $260.56.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insiders Place Their Bets

In related news, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the transaction, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. This trade represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is currently owned by company insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.